1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial
    Meeting Abstract

    D'Amico, A. V.; Xie, W.; McMahon, E.; Loffredo, M.; Medeiros, S.; Joseph, D. J.; Denham, J. W.; Lamb, D. S.; Kumar, P.; Bubley, G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms
    Meeting Abstract

    Hutson, T. E.; Choueiri, T. K.; Motzer, R. J.; Rha, S. Y.; Alyasova, A.; Merchan, J. R.; Gurney, H.; Peer, A.; Takagi, T.; Porta, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Saad, F.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F.; Goodman, O.; Oudard, S.; Steuber, T.; Suzuki, H.; Pieczonka, C. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinib
    Meeting Abstract

    Massard, C.; Pant, S.; Iyer, G.; Schuler, M. H.; Witt, O.; Qin, S.; Tabernero, J.; Doi, T.; Hargrave, D. R.; Hammond, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Porta, C.; Alekseev, B.; Rha, S. Y.; Choueiri, T. K.; Mendez-Vidal, M. J.; Hong, S. H.; Kapoor, A.; Goh, J. C.; Eto, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A prospective phase 2/3 study of PSMA-targeted (18)F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging
    Meeting Abstract

    Durack, J. C.; Alva, A. S.; Preston, M. A.; Pouliot, F.; Saperstein, L.; Carroll, P. R.; Pienta, K. J.; Rowe, S. P.; Patnaik, A.; Probst, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study
    Meeting Abstract

    Rosenberg, J. E.; Gajate, P.; Morales-Barrera, R.; Lee, J. L.; Necchi, A.; Penel, N.; Zagonel, V.; Sierecki, M. R.; Bao, W. C.; Zhou, Y. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101
    Meeting Abstract

    Albiges, L.; Voss, M. H.; Rini, B. I.; Gravis, G.; Grimm, M. O.; Nathan, P. D.; Bjarnason, G. A.; Tomita, Y.; Penkov, K.; McGregor, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801)
    Meeting Abstract

    McKay, R. R.; Jacene, H.; Atherton, P. J.; Burbano, G. P.; Ajmera, A.; Baghaie, S.; Koball, J.; Zemla, T. J.; Chen, R. C.; Choudhury, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study
    Meeting Abstract

    O'Donnell, P. H.; Balar, A. V.; Vuky, J.; Castellano, D.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Grivas, P.; Hahn, N. M.; Plimack, E. R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save